NorthStar Medical Radioisotopes LLC and Purdue University’s College of Pharmacy announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program. As part of the collaboration, NorthStar has provided a RadioGenix System to the College of Pharmacy for use in training nuclear pharmacy students on the production of technetium-99m (Tc-99m), currently the most widely used medical radioisotope for critical diagnostic imaging tests in the United States. Access to the RadioGenix platform provides nuclear pharmacy students the opportunity to become familiar with the equipment, which uses domestically sourced, non-uranium target material and an environmentally friendly production process to produce Tc-99m. As part of its user experience, the College of Pharmacy is providing NorthStar with feedback about the RadioGenix System and early testing of planned enhancements.
“We will use the RadioGenix System to provide ‘hands-on’ laboratory-based experiences so that our student pharmacists have access to the latest advancements in radiopharmacy production techniques and are well-equipped for the professional workplace,” said Eric L. Barker, Ph.D. dean, Purdue College of Pharmacy.
“Our relationship with NorthStar has provided our students with a unique insight into this exciting new development in nuclear pharmacy practice, and as they move out of academia and begin practice, they are able to better understand the pivotal role that a domestic supply of Mo-99 will play in the future,” said Kara D. Weatherman, PharmD, BCNP, FAPhA, clinical associate professor of Pharmacy Practice, director, Nuclear Pharmacy Programs, Purdue College of Pharmacy. “In addition, our use of the NorthStar RadioGenix System provides a stable supply of Mo-99/Tc-99m that can be used for our educational and research endeavors involving our pharmacy students. It will further benefit our students as they work through our nuclear pharmacy curriculum.”
“Because the RadioGenix System uses non-uranium based molybdenum-99 (Mo-99), it ensures that radiopharmacies can have stable, reliable access to domestically produced Mo-99 to produce Tc-99m,” said Stephen Merrick, President and CEO of NorthStar Medical Radioisotopes. “This in turn enables reliable scheduling of procedures to meet patients’ healthcare needs in a timely manner.”